title: Oxaliplatin, irinotecan, and fluorouracil/folinic acid in advanced gastric cancer: a multicenter phase II trial of the Southern Italy Cooperative Oncology Group.
abstract: OBJECTIVE
  This phase II trial assessed the tolerability and efficacy of a triplet of oxaliplatin, irinotecan, and fluorouracil/folinic acid in advanced gastric cancer.
  
  
  METHODS
  Patients with unresectable or metastatic gastric cancer, unexposed to palliative chemotherapy, received oxaliplatin 85 mg/m(2) iv and irinotecan 150 mg/m(2) iv on day 1, 6S-folinic acid 250 mg/m(2) iv and fluorouracil 750 mg/m(2) iv on day 2, every 2 weeks. Response rate (RR) was assessed after a minimum of four cycles, and treatment continued up to 12 cycles.
  
  
  RESULTS
  Sixty-three patients were treated, with a median of eight (range 1-12) cycles/patient. Two complete and 19 partial responses were registered (RR 33% [95% CI, 22-46%]). Median progression-free survival was 7.5 (95% CI, 5.6-9.4) months, and median overall survival was 12.1 (95% CI, 10.8-13.4) months. Most common grade > or =3 toxicities were neutropenia (59%), febrile neutropenia (7%), vomiting (20%), and diarrhoea (10%). All-grade neurotoxicity affected 33% of patients.
  
  
  CONCLUSIONS
  Oxaliplatin, irinotecan, and fluorouracil/folinic acid administered every 2 weeks are safe and active in advanced gastric cancer.
authors.affiliation: Unit of Medical Oncology, Department of Gastrointestinal Tumours, National Tumour Institute, Naples, Italy. pasqualecomella@libero.it
authors.forename: Pasquale
authors.initials: P
authors.lastname: Comella
authors.forename: Vito
authors.initials: V
authors.lastname: Lorusso
authors.forename: Luigi
authors.initials: L
authors.lastname: Maiorino
authors.forename: Rossana
authors.initials: R
authors.lastname: Casaretti
authors.forename: Michele
authors.initials: M
authors.lastname: Cannone
authors.forename: Bruno
authors.initials: B
authors.lastname: Massidda
authors.forename: Carlo
authors.initials: C
authors.lastname: Putzu
authors.forename: Silvana
authors.initials: S
authors.lastname: Leo
authors.forename: Mario
authors.initials: M
authors.lastname: Roselli
authors.forename: Sergio
authors.initials: S
authors.lastname: Mancarella
authors.forename: Sergio
authors.initials: S
authors.lastname: Palmeri
authors.forename: Ettore
authors.initials: E
authors.lastname: Greco
authors.forename: Giacomo
authors.initials: G
authors.lastname: Vessia
authors.forename: Claudia
authors.initials: C
authors.lastname: Sandomenico
authors.forename: Luca
authors.initials: L
authors.lastname: Franco
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000931:Antidotes / Q000008:administration & dosage; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001772:Blood Cell Count; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D000077146:Irinotecan; D053208:Kaplan-Meier Estimate; D002955:Leucovorin / Q000008:administration & dosage; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016019:Survival Analysis; D014057:Tomography, X-Ray Computed
chemical_list: D000931:Antidotes; D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D000077146:Irinotecan; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin